PCSK9 Forum
22nd July 2015
Facebook Twitter RSS YouTube
For latest updates
Register today
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact

Hot news: world first
Evolocumab approved in Europe

Evolocumab is the first PCSK9 inhibitor approved in Europe for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein (LDL) cholesterol reduction. Evolocumab is the first of these novel treatments to be approved.

The promise of the PCSK9 inhibitors is now a reality for clinicians in the space of a decade.

Read the full report »

FDA gives nod to alirocumab, evolocumab
PCSK9 Forum Ed Board response

At meetings of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA), the Committee recommended approval of the PCSK9 monoclonal antibodies alirocumab and evolocumab.

Read the report »

Professors John Chapman and Henry Ginsberg
New era in cholesterol-lowering?

New era

Professor Philip Barter
New cholesterol lowering drugs in the news

New cholesterol lowering drugs in news


Professor Steven Nicholls
How will PCSK9 inhibitors be used in practice?

How will PCSK9 inhibitors be used in practice?

Easy access to e-book
Understanding PCSK9 inhibition
Free for healthcare professionals

Prepared by independent experts from PCSK9 Education and Research Forum.

Available free to registered members of the Forum.

Register and read online »    Download now »
PCSK9 Inhibition Handbook
Invite colleagues to listen to the podcasts and read the introductory guide by joining the PCSK9 Forum

Forward to your colleagues now »
Like us on Facebook
For the latest updates on conferences, PCSK9 news and video reports.
Follow us on Twitter
For updates on hot topics,
PCSK9 news and conference reports.
YouTube Channel
For the latest videos, interviews and webcasts from leading experts.
Supported by educational grants from: Amgen Lilly pFizer Sanofi
Copyright PCSK9 Forum 2015. Please click here to unsubscribe from future mailings.